Decades of basic research in oncology are paying off, resulting in an unprecedented number of drug approvals, said Ned Sharpless, the NCI director who is set to become FDA acting commissioner.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
